WINNIPEG, Manitoba, Feb. 26, 2026 (GLOBE NEWSWIRE) -- Emergent BioSolutions (NYSE: EBS) today announced a series of new contracts and a contract modification with the Public Health Agency of Canada (PHAC) and the Department of National Defence (DND) to deliver critical medical countermeasures to support Canada’s biological threat preparedness and response infrastructure. The multiyear agreements, valued at up to approximately $140 million CAD, build upon over a decade of collaboration between Emergent and C ...

Core Insights - The Russell 2000 index has increased by approximately 2.5% in the five days ending September 19, coinciding with a Federal Reserve interest rate cut, which is seen as a potential start of a deeper rate cut cycle in the next 12 months [1][2] Group 1: Small-Cap Stocks and Interest Rates - Lower interest rates are typically favorable for small-cap stocks, especially those that are unprofitable and rely on debt for operations [2] - Analyst support, business fundamentals, and risk profiles are crucial factors for stock purchases, beyond just rate cuts [3] Group 2: Identiv (INVE) - Identiv has a market cap of over $80 million and specializes in RFID and NFC technologies, with a current stock price of $3.68 and a 12-month price forecast of $5.33, indicating a potential upside of 45.09% [4][6] - Despite a revenue decline from $6.74 million to $5.04 million year-over-year, the stock has gained approximately 18% over the past three months due to a strategic pivot towards higher-margin businesses [5][6] - Analysts maintain a consensus Buy rating for Identiv, with a price target suggesting a 47% increase from current levels [6] Group 3: Immersion (IMMR) - Immersion operates in the haptic technology market, valued at $4 billion to $5 billion, with a projected CAGR of 7-10% over the next five to seven years [8][9] - The company primarily earns revenue through licensing its technology, positioning itself as a leader in the haptic space [9] - Analysts have a bullish outlook on Immersion, with a consensus price target of $12.25, representing a potential gain of 67% from current trading levels [10] Group 4: Emergent BioSolutions (EBS) - Emergent BioSolutions has a market cap of $432 million and focuses on supplying medical countermeasures to the U.S. government, providing stable revenue streams through government contracts [12][13] - The company was awarded contracts totaling over $90 million in September 2025, ensuring stable cash flows amid market volatility [14] - Analysts project a price target of $13.50 for Emergent, indicating a potential upside of 52.77% from its current price of $8.84 [12][16]